

FMHL/SEC/SE/BM/JULY'16

July 19, 2016

The General Manager  
Department of Corporate Services  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

**Scrip Code: 523696**  
**Sub: Outcome of the Board Meeting**

Dear Sir

This is to inform you that the Board of Directors of the Company at their meeting held today i.e. July 19, 2016, *inter-alia*, considered and approved the following:

- a) Un- audited Financial Results and Limited Review Report of the Company for the quarter ended on June 30, 2016.
- b) Mr. Daljit Singh, Director of the Company, is liable to retire by rotation at the ensuing Annual General Meeting and being eligible offers himself for re-appointment.
- c) Regularization of Mr. Meghraj Arvindrao Gore as Director of the Company at the ensuing Annual General Meeting.
- d) Convening of 25<sup>th</sup> Annual General Meeting of the Company on Tuesday, September 27, 2016 at 10.00 A.M. at PHD Chamber of Commerce and Industry, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi – 110 016.
- e) Closure of Register of Members and Share Transfer Books of the Company from Tuesday, September 20, 2016 to Tuesday, September 27, 2016 (both days inclusive) for the purpose of declaration of Dividend and Annual General Meeting. The cut-off date for reckoning members eligible for voting shall be September 20, 2016.


Please find enclosed 'Un- audited Financial Results' of the Company and 'Limited Review Report' thereon for the quarter ended June 30, 2016 along with a copy of the press release being issued in this regard.

The meeting concluded at 3:00 p.m.

This is for your information and records please.

Yours faithfully

**For Fortis Malar Hospitals Limited**

  
**Sumit Goel**  
Company Secretary



**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2016**

Particulars		(Rs. in lakhs except EPS)	
		Standalone Quarter ended	
		June 30, 2016 (Unaudited)	June 30, 2015 (Unaudited) Refer Note 2 below
<b>1</b>	<b>Income from Operations</b>		
	a) Income from Operations	3,300.65	3,005.56
	b) Other Operating Income	0.88	12.73
	<b>Net Income from Operations</b>	<b>3,301.53</b>	<b>3,018.29</b>
<b>2</b>	<b>Expenses</b>		
	a) Purchase of Medical Consumables and Drugs	717.98	827.19
	b) Changes in Inventories of Medical Consumables and Drugs	(32.98)	(119.59)
	c) Employees Benefit Expenses	471.43	407.20
	d) Professional Charges to Doctors	1,017.11	782.20
	e) Clinical Establishment Fees	485.00	455.70
	f) Depreciation and Amortization Expenses	93.86	78.36
	g) Other Expenses	628.76	523.51
	<b>Total Expenses</b>	<b>3,381.16</b>	<b>2,954.57</b>
<b>3</b>	<b>(Loss) / Profit from Operations before Other Income &amp; Finance Costs (1-2)</b>	<b>(79.63)</b>	<b>63.72</b>
<b>4</b>	<b>Other Income</b>	<b>180.04</b>	<b>191.47</b>
<b>5</b>	<b>Profit before Finance Costs (3 + 4)</b>	<b>100.41</b>	<b>255.19</b>
<b>6</b>	<b>Finance Costs</b>	<b>8.62</b>	<b>9.19</b>
<b>7</b>	<b>Profit from Ordinary Activities before Tax (5 - 6)</b>	<b>91.79</b>	<b>246.00</b>
<b>8</b>	<b>Tax expense</b>	<b>31.76</b>	<b>84.65</b>
<b>9</b>	<b>Net Profit from Ordinary Activities After Tax (7-8)</b>	<b>60.03</b>	<b>161.35</b>
<b>10</b>	<b>Other Comprehensive Income</b>	<b>-</b>	<b>(1.01)</b>
<b>11</b>	<b>Total Comprehensive Income for the period (9+10)</b>	<b>60.03</b>	<b>160.34</b>
<b>12</b>	<b>Paid up Equity Share Capital (Face Value Rs.10 each)</b>	<b>1,862.08</b>	<b>1,860.95</b>
<b>13</b>	<b>Earnings Per Share (EPS) (of Rs. 10 each)</b>		
	- Basic	0.32	0.87
	- Diluted	0.32	0.87
		[Not Annualised]	[Not Annualised]


**Notes:**

- The above unaudited financial results have been reviewed by the Audit and Risk Management Committee, approved and taken on record by the Board of Directors in their meeting held on July 19, 2016. The unaudited results for the Quarter ended June 30, 2016 has been subjected to a limited review by the Statutory Auditors of the Company.
- The financial results pertaining to the quarter ended June 30, 2015 have not been subjected to a limited review or audit and have been presented based on the information compiled by the Management. The Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs in accordance with the Indian Accounting Standards (Ind AS).
- The Company adopted Ind AS from April 1, 2016 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. The reconciliation between standalone financial results for the quarter ended June 30, 2015, as previously reported (referred to as Previous GAAP) and Ind AS is as under:


Particulars	Rs. in lakhs
Net Profit under Previous GAAP	160.79
Actuarial Loss on employee defined benefit plans recognised in Other Comprehensive Income	1.01
Straight lining of Clinical Establishment Fees	(0.91)
Fair value adjustments for Financial Assets	0.46
<b>Net Profit for the period under Ind AS</b>	<b>161.35</b>
Other Comprehensive Income	(1.01)
<b>Total Comprehensive Income under Ind AS</b>	<b>160.34</b>

- The Company has identified business segment which is "Health Care Services" as its primary segment and geographic segment as its secondary segment. The amounts appearing in the results relate to this single primary segment.
- The results for the quarter ended June 30, 2015 have been restated to comply with Ind-AS to make them comparable with the current period. Further, previous period figures have been regrouped / reclassified, wherever necessary, to conform with the current period presentation.

By Order of the Board  
For and on Behalf of Board of Directors

  
Raghunath P  
Whole Time Director

Place: Chennai  
Date: July 19, 2016




## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF FORTIS MALAR HOSPITALS LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **FORTIS MALAR HOSPITALS LIMITED** ("the Company") for the Quarter ended June 30, 2016 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement which, is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. We have not reviewed the financial results and other financial information for the Quarter ended June 30, 2015 which have been presented solely based on the financial information compiled by the Management.

For **DELOITTE HASKINS & SELLS LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



A handwritten signature in black ink, appearing to read "Rashim Tandon".

**Rashim Tandon**  
Partner  
(Membership No. 095540)

CHENNAI, July 19, 2016


**FORTIS MALAR REPORTS Q1FY17 REVENUE AT RS.33.01 CR,  
OPERATING PROFIT FOR THE QUARTER AT RS 0.14 CR**

**Chennai, July 19, 2016:** Fortis Malar Hospitals Limited, a subsidiary of Fortis Healthcare Limited, a leading integrated healthcare delivery provider in India, today announced its results for the quarter ended June 30, 2016.

**Commenting on the results Mr Daljit Singh, Chairman, Fortis Malar Hospitals Limited,** said, “The hospital has distinguished itself for its distinctive tertiary care medical services in Chennai. It has been setting newer benchmarks in medical care by continually undertaking high end and complex surgeries, particularly in cardiology, neurology, mother and child care. The hospital also achieved the unique distinction of completing over 100 heart transplants, which reinforces the position that Fortis Malar enjoys as a high quality super specialty tertiary care centre. I am very pleased with the results and the medical outcomes at the hospital and am confident that we will continue to deliver world class clinical programmes, in the future as well.”

**Financial Highlights for the Quarter (Q1FY2017).**

- Fortis Malar Hospitals reported an operating revenue of Rs 33.01 Cr compared to Rs 30.19 Cr in the corresponding quarter of the previous year.
- Operating profit for the quarter stood at Rs 0.14 Cr compared to Rs 1.42 Cr, in the corresponding quarter of the previous year.
- Net profit was at Rs 0.60 Cr compared to Rs.1.61 Cr, in the corresponding period, last fiscal.
- During the quarter, Fortis Malar witnessed growth in its key specialties, showing a markedly better performance in CTVS, Renal and Gynecology which grew by 47%, 8% and 18% respectively, compared to the corresponding quarter of the previous year.



### **Operational Highlights for the quarter**

- Fortis Malar successfully completed 100 Heart Transplants and 16 Transplants in this quarter, thereby positioning itself amongst the pre-eminent heart transplant centers of the world.
- The expert medical team at the hospital continued to perform high risk and rare surgeries. During the quarter, the team performed the following complex surgeries:
- 16 Knee & 4 HIP Replacements were also performed at the hospital during the quarter.

### **Corporate Social Responsibility**

Playing its part as a good social corporate citizen, Fortis Malar has been involved in activities that contribute to society. The following CSR activities were undertaken during the quarter:

- A health check up program for the poor.
- An Ortho Camp with Rotary club was conducted during the quarter.

### **About Fortis Malar Hospitals Ltd**

Fortis Malar Hospital (formerly known as Malar Hospital) was acquired by Fortis Healthcare (India) Limited in early 2008. The hospital founded in 1992, is established as one of the largest corporate hospitals in Chennai providing quality super specialty and multi-specialty healthcare services. Fortis Malar Hospitals, with 180 beds, focuses on providing comprehensive medical care in the areas of Cardiology and Cardiac Surgery, Neuro Surgery, Gynaecology, Orthopaedics, Gastroenterology, Neurology, Paediatrics, Diabetics, Nephrology and Internal Medicine.

Fortis Malar Hospital has a state of the art Cath Lab and multiple dedicated cardiac operation theatres and intensive coronary care units. Several rare and complex Adult and Paediatric Cardiac surgeries, Orthopedic and Joint replacements, Neurosurgeries and Plastic reconstruction surgeries have been performed at this hospital. The hospital's Obstetrics and Gynaecology services are among the busiest in the city, successfully performing many complicated deliveries and surgeries. They are supported by a dedicated Neonatology unit.

### **About Fortis Healthcare Ltd**

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Dubai, Mauritius



and Sri Lanka with 54 healthcare facilities (including projects under development), approximately 10,000 potential beds and 280 diagnostic centres

**DISCLAIMER**

*This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.*

**FOR MORE INFORMATION PLEASE CONTACT**

**Mr .Venkata Ramanan D**

PR & Communications

Fortis Malar Hospitals Ltd

Mobile: 8939831212

[Venkata.ramanan@fortishealthcare.com](mailto:Venkata.ramanan@fortishealthcare.com)

**Sumit Jain**

K2 Communications Pvt Ltd

Mobile: 9886021715

[Sumit.jain@k2communications.in](mailto:Sumit.jain@k2communications.in)

